NASDAQ: EXPO · Engineering & Construction

Exponent (EXPO) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values Exponent (EXPO) at $81.75 a share. The stock last closed at $88.18, which puts the model's fair value 7.3% below the price. On the model's bands that reads as Fairly valued.

Revalued . Price is the close of 16 Nov 2026. Exponent, Inc.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$81.75midpoint of 2,000 simulations
Last close$88.18NASDAQ: EXPO
Gap to fair value-7.3%fair value against price
Model verdictFairly valuedevidence grade: High

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $78.27 to $81.75 (+4.4%). The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move.

What the model makes of itThe price of $88.18 is 7.3% above it: Fairly valued, on a high evidence grade.

What's nextNext report on 4 Feb 2027. Options prices imply a move of about 10% either way over the next month. On the model's Quality Momentum list since 9 Nov 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give EXPO?

The calibrated range for EXPO over 63 trading days is $78.91 to $99.09. It sits around the last close, and its width comes from the volatility that EXPO's own options imply (34% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $68.20 to $97.00. In 38% of the simulations the fair value came out above the price the model ran on.

$55.05$120.78
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $81.75. Dashed line: the last close, $88.18.

Faircurve Insights · 14 Nov 2026

Exponent, Inc. is a global leader in scientific and engineering consulting, working through its subsidiaries. Its activities fall into two segments: Engineering and Other Scientific, and Environmental and Health.

Faircurve's model put the fair value at $81.75 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $78.27, so the fair value moved +4.4%. The model's reason: the stock's own trading multiple rose, and the fair value follows it in part, most of the move. The calibrated range over 63 trading days is $78.91 to $99.09. It is built from the volatility the stock's own options imply and calibrated weekly against realised prices, using 8,038 past valuations refreshed on 14 Nov 2026. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is High, based on input completeness, the number and agreement of comparables, and the width of outcomes. It does not say whether the fair value is right.

The business scores 80 out of 100 on the model's quality measure against comparable companies. Three factors stand out at 100: profitability, with ROIC of 36.6% against a peer median of 13.3%; balance sheet, with net debt to EBITDA of -0.21x against 2.60x; and stability, with EBITDA margin downside volatility of 0.4 pts against 1.3 pts. The model compares it with MYRG, AGX, ECG, PRIM, GVA, FLR and DY. KBR has no verdict on this date.

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does EXPO report earnings, and how has the stock reacted?

Exponent's next earnings report is scheduled for 4 Feb 2027. Companies can move their dates.

On 16 Nov 2026, EXPO's 30 day implied volatility worked out to a move of about 9.7% over one month, in either direction. That is a size, not a direction.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across EXPO's last 8 reports, ignoring direction, was 3.0%.

0%5%10%15%no quote9.5%24 Oct '24no quote1.8%6 Feb '2512.5%0.7%31 Jul '25no quote8.3%30 Oct '25no quote13.8%5 Feb '26no quote1.4%30 Apr '26no quote1.5%30 Jul '268.9%4.1%29 Oct '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in EXPO

5%10%15%20%29 Oct '26 report10% at 13 Nov '262 Sep '2613 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 9% on 2 Sep 2026, reached 13% on 22 Oct 2026 and reads 10% on 13 Nov 2026. The marks are report dates.

How does EXPO score on business quality?

Exponent's overall quality score is 80 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.10036.6%ROIC13.3%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).741.23xFCF / net income1.15x
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.524.2%Revenue growth, trailing0.6%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.434.1%Net buybacks / market value3.8%
Balance sheetNet debt to EBITDA and interest coverage.100-0.21xNet debt / EBITDA2.60x
StabilityDownside volatility of the EBITDA margin over the last five years.1000.4 ptsEBITDA margin downside volatility, 5y1.3 pts

How does EXPO compare with similar companies?

The companies in engineering & construction closest to Exponent in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
MYRG MYR Group Inc.$267.85$261.90-2.2%Fairly valued
AGX Argan, Inc.$294.36$290.96-1.2%Fairly valued
ECG Everus Construction Group, Inc.$82.92$96.37+16.2%Undervalued
KBR KBR, Inc.$35.35$40.97+15.9%Low evidence grade
PRIM Primoris Services Corporation$67.14$69.96+4.2%Fairly valued
GVA Granite Construction Incorporated$122.24$137.36+12.4%Fairly valued
FLR Fluor Corporation$48.39$56.17+16.1%Undervalued
DY Dycom Industries, Inc.$215.39$229.88+6.7%Fairly valued

What the comparable companies' multiples alone would give for EXPO, the peer-implied price, is $65.70 a share on this run. The fair value weighs that against the company's own multiple.

All engineering & construction stocks ranked by gap to fair value

Exponent at a glance

Exponent, Inc. functions as a global leader in scientific and engineering consulting, operating through its subsidiaries. The firm's activities are divided into two principal segments: Engineering and Other Scientific, and Environmental and Health.

Market value
$4.2B
Sector
Industrials
Industry
Engineering & Construction
Revenue expected, next twelve months
$637M
Consensus revenue growth, next fiscal year
+2.1%
Analysts with estimates
3
Beta to the US market
0.29
First valued by Faircurve
11 Jul 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. EXPO was not among them.

How the fair value is worked out: the model prices Exponent on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for EXPO was $78.27. As of 14 Nov 2026 it is $81.75, a change of +4.4%. The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Exponent's valuation

Is Exponent stock undervalued or overvalued?

On Faircurve's model, EXPO reads as Fairly valued as of 14 Nov 2026. The model's fair value is $81.75 a share against a last close of $88.18, a gap of -7.3%.

What is EXPO's fair value?

$81.75 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $68.20 to $97.00.

What price range does the model give EXPO?

$78.91 to $99.09 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Exponent report earnings next?

The next report is scheduled for 4 Feb 2027. Companies can move their dates.

How much has EXPO moved on past earnings reports?

Across its last 8 reports the median two session move was 3.0%, ignoring direction. The largest was +13.8% around the report of 5 Feb 2026.

How confident is the model in this valuation?

The model's evidence grade for EXPO is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on EXPO

The model has an idea open on EXPO under Quality Momentum since 9 Nov 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on EXPO with their outcomes. A free account is enough.

Keep reading